TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of any of the following B-cell chronic LPD, as defined by WHO 2008 classification: small lymphocytic lymphoma/chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, Hodgkin's lymphoma.~2. Occurrence of ITP diagnosed on the basis of predefined criteria.~3. Not likely to necessitate any cytotoxic treatment for the following 6 months, according to clinical stage and performance status.~4. Platelet count less than 30,000/µL; patients with platelet count between 30 and 50,000/µL only in case of bleeding signs or symptoms.~5. Age greater than or equal to 18 years.~6. Absence of a personal or family (up to first degree relatives) history of venous or arterial thromboembolism.~7. ECOG performance status ≤2.~8. Adequate liver and renal function.~9. Absence of active Hepatitis B (HBsAg+ or HBV-DNA+), Hepatitis C (HCV-Ab+), or HIV infection.~9) Provided informed consent. 10) Negative pregnancy test or lactation 11) No antiplatelet or anticoagulant ongoing treatments~Exclusion Criteria:~1. Subjects with any clinically relevant abnormality, other than LPD or ITP, or any other medical condition or circumstance, which in the opinion of the investigator makes the subject unsuitable for participation in the study.~2. Subjects with any concurrent malignant disease other that the LPD and/or a recent history of cancer treatment with systemic chemotherapy and/or radiotherapy. Exception: Subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.~3. Subjects with screening bone marrow fibers of either MF Grade 3 using European Consensus scale or Grade 4 using Bauermeister scale (see Appendix 1).~4. Subjects with a QTc \>450 msec or \> 480 msec for subjects with Bundle Branch Block.~5. Subjects with recent history of alcohol/drug abuse as determined by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eltrombopag Olamine (Type: OTHER): Eltrombopag Olamine Initial dose 50 mg/day for 14 days. Then adjusted according to platelet count

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Validation of an Artificial Intelligence-based Algorithm for Skeletal Age Assessment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Exams that meet the following inclusion criteria will be included: (1) exams read by radiologists who interpret pediatric skeletal age exams and verbally consent to participate (2) exams that contain a procedure code or study description indicative of a skeletal age exam.~Exams containing more than one radiograph will not be included. Exams for which a trainee provides a preliminary interpretation will be excluded. No further exclusion criteria will be applied on the basis of image quality metrics or manufacturers. No exclusion criteria will be applied on the basis of patient chronological age.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Without-AI) (Type: NO_INTERVENTION): This is the control arm where no intervention is provided; represents current standard of care.
- Experiment (With-AI) (Type: EXPERIMENTAL): This is the experiment arm where the intervention, BoneAgeModel, is provided. The participating radiologists in this arm will receive the output of the Artificial Intelligence algorithm. They will be asked to incorporate this new information with their normal workflows to make a diagnosis. The radiologists' diagnosis will be considered final.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 6-14 year old children with a history of asthma for at least 12 months~* must demonstrate airway constriction brought on by exercise~Exclusion Criteria:~* is taking any medications that are not allowed in the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast/Salmeterol (Type: EXPERIMENTAL): Period I - Montelukast 5 milligrams (mg) oral tablet once daily and Salmeterol matching placebo dry powder inhaler (DPI) twice daily for 4 weeks followed by a 2-week washout period (salmeterol matching placebo + montelukast matching placebo). Period II - Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 micrograms (mcg) twice daily for 4 weeks. Inhaled Fluticasone 100 mcg twice daily throughout the study.
- Salmeterol/Montelukast (Type: EXPERIMENTAL): Period I - Montelukast matching placebo oral tablet once daily and Salmeterol DPI 50 mcg twice daily for 4 weeks followed by a 2-week washout period (salmeterol matching placebo + montelukast matching placebo). Period II - Montelukast 5 mg oral tablet once daily and Salmeterol matching placebo DPI twice daily for 4 weeks. Inhaled Fluticasone 100 mcg twice daily throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be HIV positive with Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) values that are within ranges required by the study~* Patient must be currently on antiretroviral therapy (ART)~Exclusion Criteria:~* Patient less than 18 years of age~* Additional exclusion criteria will be discussed and identified by the study doctor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MK0518 200 mg
- 2 (Type: EXPERIMENTAL): MK0518 400 mg
- 3 (Type: EXPERIMENTAL): MK0518 600 mg
- 4 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1.Provision of written informed consent prior to any study-related procedures/examinations 2.Aged 20 years and older 3.Subjects who are planned to undergo a non-emergent EGD or colonoscopy, including gastrointestinal endoscopic polypectomy that shall be completed within 1 hour (excluding the endoscopic submucosal dissection and ultrasonic endoscope, pernasal endoscope, etc.). Exclusion Criteria:~1. involvement in the planning and/or conduct of the study (applies to both sponsor's employees and/or staffs at the study site)~2. Subjects who underwent a endoscopic procedure under ICI35,868 (propofol) administration within 1 year.~3. Participation in another clinical study with an investigational product within 4 weeks prior to randomisation.~4. Baseline (Visit 1) of blood oxygen saturation (SpO2)\<90% (room air)~5. ASA III, IV, V and VI ; Subject with serious disease of cardiovascular, respiratory, renal, liver, pancreatic or endocrine function.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: PLACEBO_COMPARATOR): Group 1 (placebo group) is treated by Anaesthesiologist
- Group 2 (Type: ACTIVE_COMPARATOR): Group 2 (ICI35,868 without EES0000645/A) is treated by Anaesthesiologist
- Group 3 (Type: ACTIVE_COMPARATOR): Group 3 (ICI35,868 with EES0000645/A) is treated by Endoscopist

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Patients with visual impairment secondary to branch retinal vein occlusion (BRVO) with a BCVA between 19 and 73 letters in one eye and at least 35 letters in the other eye.~Exclusion Criteria:~* Pregnant or nursing women or women of child bearing potential without unless using an effective contraception~* Stroke or myocard infarction within 3 months prior to study~* History of malignancy within the past 5 years~* Uncontrolled hypertension~* Active infection or inflammation in any eye~* use of corticosteroids for at least 30 days in the last 6 months~* treatment with anti-angiogenic drugs in any eye within last 3 months~* Panretinal or focal/drid laser photocoagulation within the last few months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab 0.5 mg (Type: EXPERIMENTAL): PRN Intravitreal injection
- Sham injection (Type: SHAM_COMPARATOR): As of Month 6 ranibizumab 0.5 mg PRN intravitreal injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy 2 month infants, available for entire study period and parent/legal guardian reachable by telephone~* Able to complete three blood draws during study~* At least 3.5 kg at enrollment~Exclusion Criteria:~* Previous vaccination (except Hepatitis, BCG), contraindication or allergic reaction to vaccines~* Immune deficiency, bleeding disorder or significant chronic medical condition

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must have successfully enrolled in either study M10-877 or M10-880 and either met the endpoint of Treatment Failure or completed the study~Exclusion Criteria:~* A participant will be excluded from this study if the participant discontinued from study M10-877 or M10-880 for any reasons other than having a Treatment Failure event~* Participant with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial~* Participants with intraocular pressure of \>= 25 mmHg and on \>= 2 glaucoma medications or evidence of glaucomatous optic nerve injury~* Participant with proliferative or severe non-proliferative diabetic retinopathy or clinically significant macular edema due to diabetic retinopathy~* Participant with neovascular/wet age-related macular degeneration~* Participant with abnormality of vitreo-retinal interface (i.e., vitreomacular traction, epiretinal membranes, etc.) with the potential for macular structural damage independent of the inflammatory process~* Participant with a systemic inflammatory disease that requires therapy with a prohibited immunosuppressive agent at the time of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: OTHER): Participants received open label (OL) adalimumab 40 mg by subcutaneous (SC) injection every other week (eow) until the final visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Adult patients 18-80 years of age~* RA for ≥ 2 months;~* Receiving outpatient treatment~* Patients naive to, and considered to be candidates for, methotrexate treatment~Exclusion criteria:~* Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA~* Inflammatory joint disease other than RA, or other systemic autoimmune disorder~* Diagnosis of juvenile rheumatoid arthritis, or RA before the age of 16~* Surgery within 12 weeks of study~* Previous treatment with any approved or investigational biologic agent for RA, an anti-alpha4-integrin antibody or co-stimulation modulator, or cell-depleting therapy~* Concurrent treatment with any biologic agent or DMARD other than methotrexate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab (0.5 g x 2) + Methotrexate (Type: EXPERIMENTAL): Rituximab intravenously at a dose of 0.5 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
- Rituximab (1.0 g x 2) + Methotrexate (Type: EXPERIMENTAL): Rituximab intravenously at a dose of 1.0 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
- Placebo + Methotrexate (Type: PLACEBO_COMPARATOR): Placebo intravenously on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.~From Week 104 participants were eligible to receive Rituximab 2 X 0.5 g or Rituximab 2 X 1.0 g every 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals age 18 years old and older with schizophrenia or schizoaffective disorder as confirmed by the Mini International Psychiatric Inventory (MINI).~2. Individuals who are currently or have been recently homeless (within the past 12 months) as per the official federal definition of homelessness.~3. Known to have medication treatment adherence (20% or more missed medications in past week or past month) problems as identified by the Treatment Routines Questionnaire patient or clinician versions (TRQ-P/TRQ-C).~4. Ability to be rated on psychiatric rating scales.~5. Willingness to take long-acting injectable medication.~6. Currently receiving treatment at a Community Mental Health Clinic (CMHC) or another mental health treatment provider who is able to provide continuity of care during and after study participation.~7. Able to provide written, informed consent to study participation.~8. Women of child-bearing potential must be utilizing reliable, medically-accepted methods of birth control.~Exclusion Criteria:~1. Known resistance or intolerance to haloperidol or haloperidol decanoate.~2. Medical contraindication to haloperidol or haloperidol decanoate.~3. Individuals on long-acting injectable antipsychotic medication immediately prior to study enrollment.~4. Prior or current treatment with clozapine.~5. Concurrent medical condition or psychiatric illness, which in the opinion of the research psychiatrist, would interfere with the patient's ability to participate in the trial.~6. Current substance dependence.~7. High risk of harm to self or others.~8. Female who is currently pregnant or breastfeeding.~9. Individual who is already in permanent and supported housing that includes comprehensive mental health services (e.g. Housing First).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient Noncompliance (Type: EXPERIMENTAL): There was only one arm for this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VIR-7831 for the Early Treatment of COVID-19 in Outpatients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must be aged 18 years or older AND at high risk of progression of COVID-19 or ≥ 55 years old~* Participants must have a positive SARS-CoV-2 test result and oxygen saturation ≥94% on room air and have COVID-19 symptoms and be less than or equal to 5 days from onset of symptoms~Exclusion Criteria:~* Currently hospitalized or judged by the investigator as likely to require hospitalization in the next 24 hours~* Symptoms consistent with severe COVID-19~* Participants who, in the judgement of the investigator are likely to die in the next 7 days~* Severely immunocompromised participants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VIR-7831 (Sotrovimab) (Type: EXPERIMENTAL): Participants received 500 mg sotrovimab administered intravenously (IV)
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered intravenously (IV)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Type 1 diabetes of at least one year duration;~2. Treated with CSII therapy for at least 6 months;~3. Age 18 to 70 years, inclusive;~4. A1C \>7.0 and ≤10% as screening;~5. BMI ≤35 kg/m2;~6. Stable insulin dose (±10%) for at least 3 months prior to screening;~7. If female, has a negative urine pregnancy test at screening;~8. If female and of childbearing potential, practicing and willing to continue to using appropriate contraception to ensure that pregnancy does not occur during the study;~9. Able to understand and sign the required study documents and comply with the protocol requirements~Exclusion Criteria:~1. Is poorly compliant with the currently prescribed insulin regimen, as determined by the investigator;~2. Has any significant medical condition, laboratory findings, or medical history that may affect successful completion of the study and/or personal well-being;~3. If female and if of childbearing potential, is pregnant, lactating, or planning to become pregnant;~4. Has experienced recurrent severe hypoglycemia requiring assistance during the past 6 months;~5. Has a history of hypoglycemia unawareness;~6. Has a confirmed diagnosis of gastroparesis;~7. Requires the use of drugs that stimulate gastrointestinal motility;~8. Is receiving medications known to interfere with glycemic control (i.e. glucocorticoids);~9. Has been treated with any oral antidiabetic agent or exenatide within 3 months of screening visit;~10. Has been treated with pramlintide within 3 months of screening visit;~11. Has received an investigational drug within 3 month of screening visit;~12. Is currently participating in a clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Interventional, continuous pramlintide infusion at 9 micrograms/hr plus 60 microgram meal bolus plus continuous insulin basal-bolus subcutaneous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete